Clinical Trial Update: A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase I study evaluating the combination of Sutent (sunitinib) and Rapamune (sirolimus) in advanced Non-Small Cell Lung Cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rapamune (sirolimus)
• Sutent (sunitinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED